Jennewein Biotechnologie, to bring innovation to baby food market

19 February 2019 | News

Human oligosaccharides (HMOs) constitute the third largest component of breast milk and are unique to humans in concentration and structural diversity.

Image not found or type unknown

Jennewein Biotechnologie GmbH, the global leader in the research and manufacture of human milk oligosaccharides (HMO), and Yili Industrial Group (Yili Group), China’s leading company, have announced the signing of a Memorandum of Understanding (MoU) on infant microbiome and human milk oligosaccharides, with the goal to develop an innovative infant formula and dairy products specifically tailored to the Chinese market.

Human milk oligosaccharides (HMOs) constitute the third largest component of breast milk and are unique to humans in concentration and structural diversity. HMOs possess several physiological effects; they confer protection against infectious diseases (e.g. noro viruses) and act as prebiotics for the development of the infant microbiome.

Today, it is widely recognized that the establishment of a healthy microbiome is key for the overall development of an infant. Failure to support a natural or healthy microbiome may potentially lead to obesity, autism or allergy development in addition to other existing issues in infant health and development. However, most infant formulas do not contain HMOs as of today. Dr Gerrit Smit, managing director of Yili Innovation Center Europe stated: “Yili Group has been dedicated to Chinese breast milk composition studies for years and has initiated the establishment of a Chinese Breast Milk Database. Yili has constantly brought innovative products to the market based on scientific research, for example Pro-Kido, and is looking forward to collaborating with Jennewein in the future.”